ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Long, Zi Jie ^a   Hu, Yuan ^a   Li, Xu Dong ^a   He, Yi ^a   Xiao, Ruo Zhi ^a   Fang, Zhi Gang ^a   Wang, Dong Ning ^a   Liu, Jia Jun ^a   Yan, Jin Song ^b   Huang, Ren Wei ^a   Lin, Dong Jun ^a   Liu, Quentin ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID;

ADOLESCENT; ADULT; ADVERSE EFFECTS; CHILD; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CHILD; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84905967757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104610     Document Type: Article

References (43)

1. Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111: 2505-2515.
2. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, et al. (1989) Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73: 1116-1122. (Pubitemid 19107411)
3. Sanz MA, Jarque I, Martín G, Lorenzo I, Martínez J, et al. (1988) Acute promyelocytic leukemia: therapy results and prognostic factors. Cancer 61: 7-13. (Pubitemid 18023103)
4. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, et al. (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72: 567-572.
5. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, et al. (2002) All-trans retinoic acid in acute promyelocytic leukemia: Longterm outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100: 4298-4302. (Pubitemid 36001941)
6. Tallman MS (2007) Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 20: 57-65.
7. 3) in the treatment of acute promyelocytic leukemia (APL): As2O3 exerts dosedependent dual effects on APL cells. Blood 89: 3345-3353.
8. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
9. Sun HD, Ma L, Hu XC, Zhang TD (1992) Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin West Med 12: 170-171.
10. Zhang P, Wang SY, Hu LH (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17: 58-62.
11. Niu C, Yan H, Yu T, Sun HP, Liu JX, et al. (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94: 3315-3324. (Pubitemid 29536124)
12. Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, et al. (2005) Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 82: 224-229. (Pubitemid 41552328)
13. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, et al. (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860. (Pubitemid 32880064)
14. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, et al. (2005) Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 102: 7653-7658.
15. Giannì M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, et al. (1998) Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91: 4300-4310. (Pubitemid 28261995)
16. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, et al. (2001) Combined effect of alltrans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97: 264-269. (Pubitemid 32061269)
17. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, et al. (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189: 1043-1052. (Pubitemid 29169821)
18. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 101: 5328-5335.
19. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, et al. (2007) Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109: 1355-1359. (Pubitemid 46466562)
20. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, et al. (2006) Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107: 3469-3473.
21. Wang G, Li W, Cui J, Gao S, Yao C, et al. (2004) An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 22: 63-71. (Pubitemid 39410010)
22. Li X, Sun WJ, Li ZJ, Zhao YZ, Li YT, et al. (2007) A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center. Leuk Res 31: 765-771.
23. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, et al. (2009) Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 106 (9): 3342-3347.
24. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, et al. (2010) Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 28(6): 1047-1053.
25. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, et al. (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 116(19): 3751-3757.
26. Quezada G, Kopp L, Estey E, Wells RJ (2008) All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatr Blood Cancer 51: 133-135. (Pubitemid 351717406)
27. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, et al. (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107: 2627-2632.
28. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, et al. (2006) Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 17: 131-134. (Pubitemid 43033852)
29. Dai CW, Zhang GS, Shen JK, Zheng WL, Pei MF, et al. (2009) Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol 121 (1): 1-8.
30. Coutre SE, Othus M, Powell B, Willman CL, Stock W, et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/ intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol doi: 10.1111/bjh.12775.
31. Asou N, Kishimoto Y, Kiyoi H, Okada M, Kawai Y, et al. (2007) A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110(1):59-66. (Pubitemid 47026819)
32. Au WY, Chim CS, Lie AK, Liang R, Kwong YL (2002) Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 117: 130-132. (Pubitemid 34304431)
33. Grigg A, Kimber R, Szer J (2003) Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia 17: 1916-1917.
34. Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, et al. (1999) Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant 24: 345-348. (Pubitemid 29377880)
35. Rock N, Mattiello V, Judas C, Huezo-Diaz P, Bourquin JP, et al. (2014) Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child. Pediatr Hematol Oncol 31(2):143-148.
36. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, et al. (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21: 2326-2334. (Pubitemid 46621871)
37. Zhang Y, Zhang Z, Li J, Li L, Han X, et al. (2013) Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 119(1):115-125.
38. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, et al. (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111-121.
39. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, et al. (2012) All - trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120(8):1570-1580.
40. Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, et al. (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very longterm results and role of maintenance. Blood 117(18):4716-4725.
41. Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, et al. (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: futher improvements in treatment outcome. Blood 115(25): 5137-5146.
42. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, et al. (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23(12):2248-2258.
43. Dos Santos GA, Kats L, Pandolfi PP (2013) Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 210(13):2793-2802.